The National Institute of Diabetes & Digestive & Kidney Disease

Type 1 Diabetes TrialNet (TrialNet)

DNA, serum, plasma, RNA, and peripheral blood mononuclear lymphocytes will be collected from the following groups and be available to the broader scientific community in the future:

• People at varying categories of diabetes risk, including those with an affected relative, with autoantibodies, and with impaired glucose tolerance. Samples will be periodically collected until the patient is diagnosed with diabetes or the end of the study period. (Natural History Study, ongoing).
• Patients with diabetes will be enrolled in randomized clinical trials. Samples will be collected at randomization, during the intervention, and during follow-up. (MMF-DZB, ongoing; Anti-CD20, planned).
• Patients in various categories of risk involved in randomized, placebo-controlled interventional clinical trials. Samples will be collected at randomization, during the intervention, and during follow-up. (Oral insulin study, planned).

Genetics of Kidneys in Diabetes (GoKinD)

• Genomic DNA from participants - now available by request;
• Serum, plasma, urine - policy for distribution being developed.

Epidemiology of Diabetes Interventions and Complications (EDIC)

Information on collaborative research opportunities utilizing DCCT/EDIC study samples could be found here.

Type 1 Diabetes Genetics Consortium (T1DGC)

Study samples (in the future) will be listed on the T1DGC website. For more information on samples to be made available, please click here.

Clinical Islet Transplantation Consortium (CIT)

Specimens (in the future) including plasma/serum/blood cell samples from patients before and after islet transplantation and from immunologic and metabolic testing.